Despite challenges in QuantiFERON sales and US life sciences caution, Qiagen NV (QGEN) maintains robust profitability and outlines strategic growth plans.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, ...

QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been ...

The company said that it expects 2026 net sales growth of 1-2% now, previously estimated at atleast 5%. ・The company pinned the lowered guidance on sustained caution among U.S. Life Sciences customers ...

Qiagen has lowered its 2026 sales growth forecast to 1–2% from at least 5%, citing weak demand for its QuantiFERON tuberculosis test, cautious U.S. Life Sciences spending, and geopolitical uncertainty ...

QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology ...

On World TB Day, milestone confirms blood test as gold standard in global fight against the disease Accurate testing can help prevent 1.5 million TB deaths annually QIAGEN expands QuantiFERON ...

QuantiFERON SARS-CoV-2 assay launched in December 2021 now CE-marked for clinical use measuring SARS-CoV-2 T-cell responses QuantiFERON-TB Gold Plus assay for TB detection set to benefit from three ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell ...

To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...